Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind comparative study versus gliclazide.
In order to investigate the clinical usefulness of glimepiride in NIDDM, some clinical trials were conducted. In a double-blind comparative study versus gliclazide, glimepiride was as efficacious as gliclazide. However, a subgroup analysis suggested glimepiride may have been more effective in severe patients treated by large doses of glibenclamide.
Tsumura
K
K
Hoechst Japan Limited, Pharma Clinical Research Department, Tokyo, Japan.
D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004311:Double-Blind Method; D005907:Gliclazide / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000032:analysis / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D001786:Blood Glucose; D005907:Gliclazide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; C057619:glimepiride